GH Research PLC develops clinical-stage mebufotenin therapies for depression, with an initial focus on treatment-resistant depression. News about GHRS centers on GH001, its proprietary inhaled mebufotenin product candidate, including clinical trial results, peer-reviewed publications, medical-conference presentations, and FDA/IND regulatory updates.
Company updates also reference GH002, its proprietary intravenous mebufotenin product candidate, and broader clinical work across depressive disorders. Recurring financial and corporate items include full-year and quarterly results, cash and capital-structure disclosures, shareholder voting matters, and business updates tied to the company’s research and development segment.
GH Research PLC (NASDAQ: GHRS) announced its business updates and financial results for Q2 2021, revealing significant developments in its clinical programs and corporate structure. The company raised $167.7 million through an IPO, issuing 11.5 million shares at $16.00 each. Cash reserves surged to $292.6 million. R&D expenses rose to $2 million due to ongoing clinical trials, while G&A expenses increased to $719,000 as a result of IPO preparations. The net loss for the quarter was $2.1 million, translating to a loss per share of $0.053.